Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H18I6N2O9 |
| Molecular Weight | 1215.8131 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=C(I)C(NC(=O)COCCOCCOCC(=O)NC2=C(I)C=C(I)C(C(O)=O)=C2I)=C(I)C=C1I
InChI
InChIKey=JXMIBUGMYLQZGO-UHFFFAOYSA-N
InChI=1S/C22H18I6N2O9/c23-9-5-11(25)19(17(27)15(9)21(33)34)29-13(31)7-38-3-1-37-2-4-39-8-14(32)30-20-12(26)6-10(24)16(18(20)28)22(35)36/h5-6H,1-4,7-8H2,(H,29,31)(H,30,32)(H,33,34)(H,35,36)
| Molecular Formula | C22H18I6N2O9 |
| Molecular Weight | 1215.8131 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Iotroxic acid (INN), also known as meglumine iotroxate (BAN) (Biliscopin) for infusion is indicated for radiological examination of the hepatic and biliary ducts and gallbladder when examination by oral technique is unsuccessful or inappropriate. Following intravenous administration Biliscopin is rapidly excreted, mainly by the liver into the bile. Visualisation of the hepatic and common bile ducts and the gallbladder can, therefore, be achieved. Visualisation of the biliary ducts is usually possible 30-60 minutes after completion of administration. In vitro meglumine iotroxate binds to plasma proteins to the extent of 60-90% depending on concentration. In animals it crosses the placental barrier. This agent is the single intravenous cholangiographic agent, which is currently available in Australia.
Approval Year
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.4 h |
70 mg/kg single, intravenous dose: 70 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
IOTROXIC ACID blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1.8 h |
112 mg/kg single, intravenous dose: 112 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
IOTROXIC ACID blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
8.19% |
IOTROXIC ACID plasma | Homo sapiens |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:32:50 GMT 2025
by
admin
on
Mon Mar 31 18:32:50 GMT 2025
|
| Record UNII |
84C5PTP9X6
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C28500
Created by
admin on Mon Mar 31 18:32:50 GMT 2025 , Edited by admin on Mon Mar 31 18:32:50 GMT 2025
|
||
|
WHO-VATC |
QV08AC02
Created by
admin on Mon Mar 31 18:32:50 GMT 2025 , Edited by admin on Mon Mar 31 18:32:50 GMT 2025
|
||
|
WHO-ATC |
V08AC02
Created by
admin on Mon Mar 31 18:32:50 GMT 2025 , Edited by admin on Mon Mar 31 18:32:50 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Iotroxic acid
Created by
admin on Mon Mar 31 18:32:50 GMT 2025 , Edited by admin on Mon Mar 31 18:32:50 GMT 2025
|
PRIMARY | |||
|
CHEMBL1651905
Created by
admin on Mon Mar 31 18:32:50 GMT 2025 , Edited by admin on Mon Mar 31 18:32:50 GMT 2025
|
PRIMARY | |||
|
3740
Created by
admin on Mon Mar 31 18:32:50 GMT 2025 , Edited by admin on Mon Mar 31 18:32:50 GMT 2025
|
PRIMARY | |||
|
100000083115
Created by
admin on Mon Mar 31 18:32:50 GMT 2025 , Edited by admin on Mon Mar 31 18:32:50 GMT 2025
|
PRIMARY | |||
|
84C5PTP9X6
Created by
admin on Mon Mar 31 18:32:50 GMT 2025 , Edited by admin on Mon Mar 31 18:32:50 GMT 2025
|
PRIMARY | |||
|
3652
Created by
admin on Mon Mar 31 18:32:50 GMT 2025 , Edited by admin on Mon Mar 31 18:32:50 GMT 2025
|
PRIMARY | |||
|
SUB08261MIG
Created by
admin on Mon Mar 31 18:32:50 GMT 2025 , Edited by admin on Mon Mar 31 18:32:50 GMT 2025
|
PRIMARY | |||
|
51022-74-3
Created by
admin on Mon Mar 31 18:32:50 GMT 2025 , Edited by admin on Mon Mar 31 18:32:50 GMT 2025
|
PRIMARY | |||
|
DB08945
Created by
admin on Mon Mar 31 18:32:50 GMT 2025 , Edited by admin on Mon Mar 31 18:32:50 GMT 2025
|
PRIMARY | |||
|
C72080
Created by
admin on Mon Mar 31 18:32:50 GMT 2025 , Edited by admin on Mon Mar 31 18:32:50 GMT 2025
|
PRIMARY | |||
|
3991
Created by
admin on Mon Mar 31 18:32:50 GMT 2025 , Edited by admin on Mon Mar 31 18:32:50 GMT 2025
|
PRIMARY | |||
|
DTXSID3048782
Created by
admin on Mon Mar 31 18:32:50 GMT 2025 , Edited by admin on Mon Mar 31 18:32:50 GMT 2025
|
PRIMARY | |||
|
IOTROXIC ACID
Created by
admin on Mon Mar 31 18:32:50 GMT 2025 , Edited by admin on Mon Mar 31 18:32:50 GMT 2025
|
PRIMARY | Description: An almost white powder. Solubility: Practically insoluble in water, benzene R, and ether R; freely soluble in methanol R and dimethylformamide R; dissolves in solutions of alkali hydroxides. Category: Used in the preparation of meglumine iotroxate as a radiocontrast medium. Storage: Iotroxic acid should be kept in a well-closed container, protected from light. Requirements: Iotroxic acid contains not less than 98.0% and not more than the equivalent of 102.0% of C22H18I6N2O9, calculated with reference to the anhydrous substance. | ||
|
256-917-3
Created by
admin on Mon Mar 31 18:32:50 GMT 2025 , Edited by admin on Mon Mar 31 18:32:50 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |